BioAtla and BeiGene codevelop CTLA4 inhibitor; BeiGene gets exclusive global rights

BioAtla and BeiGene co-develop CTLA4 inhibitor; BeiGene gets exclusive global rights

15:40 EDT 10 Apr 2019 | Elsevier Business Intelligence

BioAtla LLC and BeiGene Ltd. partnered for the development and commercialization of BioAtla’s CTLA4 inhibitor BA3071. The a...

More From BioPortfolio on "BioAtla and BeiGene co-develop CTLA4 inhibitor; BeiGene gets exclusive global rights"